1. Neyer J et al. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69–e171.
2. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342–4.
3. Qizilbash N et al. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–53.
4. Culic VJ. Excess in cardiovascular events on Mondays: could atherosclerotic plaques be more vulnerable after the weekend because of alcohol related cytokine dysregulation? Epidemiol Community Health 2005; 59: 911.
5. Zipes, Braunwald et al. Braunwald’s Heart Disease, 7e.
6. Скворцова В.И. Артериальная гипертония и цереброваскулярные нарушения. Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: Медиа Медика, 2005.
7. Devereux RB, Dahlöf B, Gerdts E et al. Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2004; 110: 1456–62.
8. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058.
9. Mancini GBJ, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996; 94: 258–6.
10. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 2002; 8: 1257.
11. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-Reactive Protein – Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs. Circulation 2001; 103: 2531–4.
12. Neal B, MacMahon S. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
13. Watanabe S, Tagawa T, Yamakawa K et al. Inhibition of the reninangiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2005; 25: 2376–80.
14. de Luca N, Mallion JM, O’Rourke MF et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17: 660–7.
15. Mogensen CE, Viberti G, Halimi S et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–71.
16. Williams B, Lacy PS, Thom SM et al. The CAFE Investigators, for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006; 113: 1213–25.
17. Fox KM, Henderson JR, Bertrand ME et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
18. Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366: 869–71.
19. Ideishi, Kikuo Arakawa, Hideko Nakashima et al. Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation. Circulation 2000; 101: 2612–7.
20. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018–22.
21. Gerdts E, Oikarinen L, Palmieri V et al. Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002; 39 (3): 739–43.
22. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45 (11): 1832–9.

О.М.Драпкина 

Первый МГМУ им. И.М.Сеченова